TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38467604
Drug: Neoadjuvant chemoimmunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoimmunotherapy with camrelizumab (200 mg), nab-paclitaxel (260 mg/m2), and cisplatin (dosage not specified)
Study: 38467716
Drug: Traditional Sound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Sound Therapy (TST)
Study: 38467945
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement (IIP) without grafting
Study: 38467945
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement (IIP) with autogenous tooth bone graft (ATBG)
Study: 38467945
Drug: Simvastatin (SMV)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin (SMV) gel mixed with ATBG around IIP
Study: 38468231
Drug: High baseline
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High baseline VEGF receptor-2 level
Study: 38468259
Drug: 2000 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg/day quercetin for 6 months
Study: 38468293
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy (EXP)
Study: 38468338
Drug: High-frequency plasma
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency plasma donors (HFPDs) donating 650 mL of plasma 3 times every 2 weeks
Study: 38468338
Drug: Regular-frequency plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular-frequency plasma donors (RFPDs) donating 650 mL of plasma 1 time every 2 weeks
Study: 38468418
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy for insomnia (CBT-I)
Study: 38469686
Drug: Immediate curative
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate curative therapy (radiotherapy or prostatectomy)
Study: 38469686
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy (endocrine therapy or observation)
Study: 38470404
Drug: Chemotherapy (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (paclitaxel or doxorubicin)
Study: 38470420
Drug: Liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8 mg subcutaneously for 6 months
Study: 38470420
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment of cardiovascular risk factors (control group) for 6 months
Study: 38470460
Drug: Nthabi health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nthabi health promotion app used on smartphones or tablets for up to 6 weeks
Study: 38471063
Drug: Third-party, single-donor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-party, single-donor fecal microbiota transplantation (FMT) administered in combination with systemic corticosteroids. Induction dose: 15 capsules per day for 2 consecutive days, followed by 3 weekly maintenance doses of 15 capsules each.
Study: 38471416
Drug: Durvalumab in
Normalized name: durvalumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab in combination with cCRT
Study: 38471508
Drug: i.p. nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.p. nivolumab monotherapy
Study: 38471711
Drug: Cemiplimab 600
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 600 mg intravenously Q4W for up to 48 weeks
Study: 38471711
Drug: Cemiplimab 600
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 600 mg intravenously Q4W
Study: 38471825
Drug: Suspension of
Normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension of Rilonacept
Study: 38471990
Drug: Mito-MES 20
Normalized name: Mito-4509
DrugBank: Mito-4509 (DB05846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mito-MES 20 mg daily for 14 days
Study: 38472381
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of absorbent pyjama pants (APP) after a 4-week run-in period.
Study: 38472696
Drug: Daridorexant 50
Normalized name: daridorexant 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daridorexant 50 mg (single and multiple doses)
Study: 38472696
Drug: Daridorexant 50
Normalized name: daridorexant 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daridorexant 50 mg (single dose)
Study: 38472696
Drug: Midazolam 2
Normalized name: midazolam 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 2 mg and Warfarin 25 mg (concomitant administration)
Study: 38473239
Drug: CC-96191, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-96191, a novel CD33/CD16a/NKG2D immune-modulating TriNKET
Study: 38473248
Drug: Besifovir (BSV)
Normalized name: Besifovir
DrugBank: Besifovir (DB15671)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Besifovir (BSV) treatment for up to 8 years
Study: 38475764
Drug: Intra-articular gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular gold micro-particles with hyaluronic acid (20 mg, 72,000 particles, 20-40 μm in diameter)
Study: 38475765
Drug: Completion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completion of planned therapies
Study: 38475765
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to systemic therapy
Study: 38475765
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to subsequent treatment
Study: 38475786
Drug: Anakinra (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (human interleukin 1 receptor antagonist)
Study: 38475822
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (AT2) therapy
Study: 38475822
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) vasopressor therapy
Study: 38476466
Drug: Pimavanserin (34
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimavanserin (34 mg, once daily)
Study: 38476961
Drug: Dichoptic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichoptic therapy with eye-tracking, 1.5 hours, 6 days per week for 1 month
Study: 38476961
Drug: Dichoptic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichoptic therapy with eye-tracking, continued for 4 months
Study: 38477675
Drug: Low-Dose Morphine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose Morphine
Study: 38477988
Drug: RSVPreF3-Mat vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVPreF3-Mat vaccine
Study: 38478042
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid (FA) dosages ranging from 0-1.6 mg combined with 10 mg enalapril maleate, taken daily for 8 weeks
Study: 38478255
Drug: Outpatient parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient parenteral antimicrobial therapy (OPAT) with anti-infective medications administered at home using elastomeric pumps for a median duration of 15 days.
Study: 38478366
Drug: Silymarin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (150 to 300 mg twice a day)
Study: 38478488
Drug: Maintain serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintain serum potassium ≥ 3.6 mEq/L
Study: 38478488
Drug: Maintain serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintain serum potassium ≥ 4.5 mEq/L
Study: 38478705
Drug: mRNA-1647 (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1647 (30, 90, 180, or 300 µg)
Study: 38479114
Drug: Combined 6-day
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined 6-day program of exercise, self-management workshops, and spa therapy
Study: 38479192
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) ketamine infusions (3 during acute phase, 4 additional if remitted)
Study: 38479748
Drug: SMC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMC with directly observed treatment (DOT) for the full course in under 5-year-old children
Study: 38479748
Drug: SMC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMC with directly observed treatment (DOT) for the full course in under 10-year-old children
Study: 38479748
Drug: SMC without
Normalized name: prosolv SMCC 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMC without directly observed treatment (DOT) for the full course in under 5-year-old children
Study: 38479803
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by interval cytoreductive surgery
Study: 38479953
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group using a conventional manual or automatic injection syringe (n=274)
Study: 38480590
Drug: CYP2C19 genotype-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C19 genotype-based personalized antiplatelet therapy; specific dosage and duration not mentioned.
Study: 38480590
Drug: Standard antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiplatelet therapy without genotype information; specific details not mentioned.
Study: 38480632
Drug: Preoperative 500
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative 500 mL fluid bolus
Study: 38481147
Drug: Web-based surveillance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based surveillance and respiratory specimen collection kits; participants monitored weekly for respiratory illness symptoms and collected specimens at symptom onset.
Study: 38481209
Drug: sirolimus 2
Normalized name: sirolimus 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sirolimus 2 mg once a day for a maximum of 60 months
Study: 38481318
Drug: Manual therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapies (specific type not detailed)
Study: 38481666
Drug: Triptorelin pamoate
Normalized name: Triptorelin Pamoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin pamoate (LHRH agonist)
Study: 38481947
Drug: Pevonedistat in
Normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pevonedistat in combination with ruxolitinib
Study: 38482462
Drug: CM326 55
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM326 55 mg every two weeks (Q2W)
Study: 38482462
Drug: CM326 110
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM326 110 mg every two weeks (Q2W)
Study: 38482462
Drug: CM326 220
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM326 220 mg every two weeks (Q2W)
Study: 38482462
Drug: CM326 220
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM326 220 mg every four weeks (Q4W)
Study: 38483145
Drug: 36-week steroid
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 36-week steroid stepwise reduction (SSR)
Study: 38483145
Drug: 48-week steroid
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 48-week steroid stepwise reduction (SSR)
Study: 38483248
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral vitamin D3 (VD3) for 6 weeks
Study: 38483309
Drug: Anlotinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib (12 mg orally once daily from days 1 to 14 every 3 weeks)
Study: 38483458
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who reported plans to initiate or adjust medications.
Study: 38483534
Drug: COVID-19 convalescent
Normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 convalescent plasma (CCP) transfusion with high antibody levels (upper 30% of study donors' antibody levels)
Study: 38483782
Drug: Selumetinib 100
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib 100 mg plus Pembrolizumab 200 mg
Study: 38483782
Drug: Selumetinib 125
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib 125 mg plus Pembrolizumab 200 mg
Study: 38483782
Drug: Selumetinib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (various doses) plus Pembrolizumab
Study: 38484130
Drug: c-Jun N-Terminal
Normalized name: CCK C-terminal octapeptide
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: c-Jun N-Terminal Kinase Inhibitor
Study: 38484251
Drug: 5 mL/5
Normalized name: Mineral Oil 2.5 ML/5 ML Oral Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL/5 injection
Study: 38484251
Drug: 10 mL/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/10 injection
Study: 38484756
Drug: Extended postnatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended postnatal prophylaxis with lamivudine syrup twice per day for 12 months or 1 month after breastfeeding discontinuation, initiated based on maternal viral load measured using Xpert HIV viral load assay.
Study: 38484853
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dry needling (DN) and spinal manipulative therapy (SMT)
Study: 38484853
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy (SMT) only
Study: 38484976
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1.9 g/d n-3 PUFAs)
Study: 38485054
Drug: Intravenous furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous furosemide (40 mg)
Study: 38485184
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg) administered every 2 weeks until disease progression, unacceptable toxicity, or for 24 months
Study: 38485189
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks (2 mg/kg up to 200 mg for pediatric patients)
Study: 38485210
Drug: Polypill (fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill (fixed-dose combination therapy including two antihypertensive agents, a statin, and aspirin)
Study: 38485490
Drug: Opioid replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid replacement therapy (ORT) with benzodiazepine (BZD) coprescription
Study: 38485490
Drug: Opioid replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid replacement therapy (ORT) alone
Study: 38486179
Drug: Telemedicine-based follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine-based follow-up with individual treatment plan, computer tablets, and home telemonitoring devices.
Study: 38486776
Drug: Two-dose primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose primary series of ancestral strain vaccine
Study: 38486776
Drug: Monovalent Beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent Beta variant booster vaccine
Study: 38486776
Drug: Ancestral or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ancestral or variant strain booster vaccine
Study: 38488388
Drug: Prenatal exposure
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal exposure to second-generation antipsychotics
Study: 38489057
Drug: Chloroprocaine 3%
Normalized name: chloroprocaine 3% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroprocaine 3% Gel
Study: 38489060
Drug: Aflibercept treatment
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept treatment
Study: 38490057
Drug: Topotecan (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (0.75 mg/m²) and Paclitaxel (TP)
Study: 38490057
Drug: Topotecan (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (0.75 mg/m²) and Cisplatin (TC)
Study: 38490230
Drug: Stepped collaborative
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepped collaborative care (once-weekly cognitive behavioural therapy for 50-60 min via telemedicine)
Study: 38490230
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (screening and referral to a health-care provider for treatment of symptoms)
Study: 38490532
Drug: 50 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g/d prune
Study: 38490532
Drug: 100 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g/d prune
Study: 38490660
Drug: LSALT peptide
Normalized name: LSALT Peptide
DrugBank: LSALT Peptide (DB16472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSALT peptide 5 mg intravenously daily for up to 14 days
Study: 38491111
Drug: Durable polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durable polymer drug-eluting stents (DP-DESs)
Study: 38491111
Drug: Biodegradable polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biodegradable polymer drug-eluting stents (BP-DESs)
Study: 38491429
Drug: hs-CRP <
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-CRP < 1.0 mg/L
Study: 38491429
Drug: hs-CRP ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-CRP ≥ 1.0 mg/L
Study: 38491559
Drug: GBC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBC plus nicotine metabolism-informed care (MIC)
Study: 38491795
Drug: Benralizumab 10/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab 10/30 mg according to weight (<35/≥35 kg)
Study: 38492010
Drug: 2 L-polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L-polyethylene glycol/ascorbate (2 L-PEG/Asc)
Study: 38492157
Drug: Pembrolizumab ±
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab ± chemotherapy
Study: 38493021
Drug: Avutometinib, FAK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avutometinib, FAK inhibitor defactinib, and their combination
Study: 38493055
Drug: Neuromuscular blocking
Normalized name: Neuromuscular blocking agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular blocking agents (n=281; 60%)
Study: 38493055
Drug: Antibiotics (n=118;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (n=118; 25%)
Study: 38493055
Drug: Cefazolin (52%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (52% of antibiotic-related reactions)
Study: 38493088
Drug: Emollient therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient therapy (not specified dosage or duration)
Study: 38493832
Drug: Aficamten 5-15
Normalized name: Aficamten
DrugBank: Aficamten (DB18490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aficamten 5-15 mg once daily for 10 weeks
Study: 38493953
Drug: Glutamine oral
Normalized name: glutamine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine oral suspension
Study: 38494157
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing regimens of cefoxitin
Study: 38494157
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cefoxitin
Study: 38494380
Drug: Androgen annihilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen annihilation therapy (AAT; leuprolide, abiraterone acetate plus prednisone, and apalutamide) plus metastasis-directed stereotactic body radiotherapy (SBRT) for 6 months
Study: 38494412
Drug: MVA-BN-WEV vaccine
Normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-BN-WEV vaccine (2 doses, 4 weeks apart)
Study: 38494525
Drug: Bacillus clausii
Normalized name: BACILLUS CLAUSII
DrugBank: Bacillus clausii (DB16537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus clausii spore probiotics (LiveSpo CLAUSY; 2 billion CFU/5 mL ampoule) at high dosages of 4-6 ampoules a day
Study: 38494526
Drug: Irreversible electroporation
Normalized name: Adult allogeneic CD4+ and CD8+ enriched T cells transduced with an anti-CD19 chimeric antigen receptor (CAR) that is site-specific integrated into the cellular genome. Adult allogeneic CD4+ and CD8+ enriched T cells, gene edited through the electroporati
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irreversible electroporation (IRE) after 3-month neo-adjuvant chemotherapy.
Study: 38494571
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg/day) with lifestyle education
Study: 38494574
Drug: Tirzepatide (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide (various doses)
Study: 38494597
Drug: Durvalumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab plus concurrent chemoradiotherapy (cCRT) with cisplatin
Study: 38494847
Drug: Lu AF82422
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AF82422 (75, 225, 750, 2250, 4500, and 9000 mg for cohorts A1-A6; 2250 and 9000 mg for cohorts B1 and B2)
Study: 38495608
Drug: Aripiprazole lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aripiprazole lauroxil (AL) treatment (441mg, 662mg, or 882mg every 4 weeks or 882mg every 6 weeks) for six months
Study: 38495608
Drug: Aripiprazole lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aripiprazole lauroxil (AL) treatment
Study: 38496619
Drug: Dasatinib plus
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib plus quercetin (senolytic treatment)
Study: 38497241
Drug: BI 690517
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 690517 40 mg